By Mauro Orru
Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer.
The Swiss pharmaceutical company said Tuesday that the phase 3 study met its primary endpoint of progression-free survival, showing that inavolisib, in combination with palbociclib and fulvestrant, delivered a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.
While Roche acknowledged that overall survival data were immature at this stage, it said it had observed a clear positive trend. The inavolisib combination was well tolerated.
The group said inavolisib is an investigational, oral targeted treatment with potential to provide durable disease control.
Write to Mauro Orru at [email protected]
